PD-1-IN-17 is primarily used in the field of immunotherapy, specifically targeting the PD-1/PD-L1 pathway, which is crucial in cancer treatment. By inhibiting the PD-1 receptor, this compound helps to enhance the immune system's ability to recognize and attack cancer cells. It is particularly valuable in the development of checkpoint inhibitor therapies, which are designed to block the mechanisms that cancer cells use to evade immune detection. This makes PD-1-IN-17 a promising candidate for treating various types of cancers, including melanoma, lung cancer, and others where the PD-1/PD-L1 pathway is implicated. Its application is also being explored in combination with other immunotherapies or traditional treatments like chemotherapy to improve overall efficacy in cancer management.